← Apellis Pharmaceuticals, Inc. (APLS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Apellis Pharmaceuticals, Inc. (APLS)
Pharmaceutical Preparations · market cap $5.3B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-06-25 (est.)
Phase 2
Pipeline
8
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Apellis Pharmaceuticals (APLS) is a commercial-stage biopharmaceutical company with 705 employees and a ~$5.25B market cap, built around its C3 complement inhibitor pegcetacoplan (APL-2). The company has achieved rapid revenue scaling — from $75M in 2022 to over $1B in 2025 — driven by approved indications in Paroxysmal Nocturnal Hemoglobinuria (PNH) and Geographic Atrophy (GA). The next meaningful catalyst is a Phase 2 readout for APL-3007 in GA, estimated around mid-2027.
The catalyst path
- 2027-06-25 (est.)Phase 2 · APL-3007, pegcetacoplan (APL-2)imp 7/10
- 2027-07-15 (est.)Phase 3 · Pegcetacoplanimp 9/10
- 2027-08-15 (est.)Phase 3 · Pegcetacoplanimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| APL2 | Phase 3 | FSGS |
| APL-2 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria |
| PEGCETACOPLAN (APL-2) | Phase 3 | Geographic Atrophy Secondary to Age-related Macular Degeneration |
| APL-9 | Phase 2 | COVID |
| APL-3007, pegcetacoplan (APL-2) | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration |
| Soliris | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria |
| APL-2, Pegcetacoplan | Phase 3 | Geographic Atrophy Secondary to Age-related Macular Degeneration |
| Pegcetacoplan | Phase 3 | C3G |
Price & technical context
3-month
+83.9%
6-month
+115.9%
12-month
+145.7%
52-wk range
$16.36–$41.12
vs 50-day MA
+26.8%
vs 200-day MA
+58.4%
Realized vol
106.0%
Max drawdown
-67.2%
Daily closes through 2026-05-13. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for APLS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.